|1.||Okuda, Y: 1 article (01/2000)|
|2.||Mukainaka, T: 1 article (01/2000)|
|3.||Yamagami, C: 1 article (01/2000)|
|4.||Tokuda, H: 1 article (01/2000)|
|5.||Ichiishi, E: 1 article (01/2000)|
|6.||Nishino, H: 1 article (01/2000)|
|7.||Motohashi, N: 1 article (01/2000)|
|8.||Saito, Y: 1 article (01/2000)|
01/24/2000 - "Structure-activity relationship in potentially anti-tumor promoting benzalacetone derivatives, as assayed by the epstein-barr virus early antigen activation."
11/01/1994 - "DCA did not alter the cytosolic activity for the GST substrates 1-chloro-2,4-dinitrobenzene (CDNB) or trans-4-phenyl-3-buten-2-one (tPBO) in tumors or surrounding liver. "
01/24/2000 - "The in vitro anti-tumor promoting activities of antimutagenic benzalacetone (4-phenyl-3-buten-2-one), its monosubstituted derivatives and related compounds, cinnamaldehydes and cinnamic acids, were evaluated by determining the inhibitory effect on Epstein-Barr virus early antigen (EBV-EA) activation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) in Raji cells. "
07/01/1994 - "Cytosolic glutathione S-transferase activity for trans-4-phenyl-3-buten-2-one in advanced tumors ranged from 42% to 66% of the activity in matched surrounding liver, whereas glutathione S-transferase activities for 1-chloro-2,4-dinitrobenzene were increased by 140% to 161%. "
12/11/1998 - "To elucidate the structure-activity relationship on the anti-tumor promoting activity, dehydrozingerone, curcumin, isoeugenol, which has no carbonyl group in the side chain, benzalacetone, which is the basic structure of dehydrozingerone, o-dehydrozingerone, which is the ortho-hydroxyl substituted compound of dehydrozingerone, and their related compounds were investigated using the in vitro short-term assay on TPA-induced EBV-EA activation. "
|2.||Epstein-Barr virus early antigen
|4.||Glutathione Transferase (Glutathione S-Transferase)